Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: Design of ICAM-1 cyclic peptides

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 6, 2004, Pages 1399-1402

  Anderson, Meagan E ^a   Yakovleva, Tatyana ^a   Hu, Yongbo ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PEPTIDE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CELL ADHESION; COLON ADENOCARCINOMA; DRUG DESIGN; DRUG SYNTHESIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; T LYMPHOCYTE;

CACO-2 CELLS; CELL ADHESION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EPITHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PEPTIDES, CYCLIC; T-LYMPHOCYTES;

EID: 1542375100     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.100     Document Type: Article

References (21)

1. Steinman L. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2253.
2. Yusuf-Makagiansar H., Anderson M.E., Yakovleva T.V., Murray J.S., Siahaan T.J. Med. Res. Rev. 22:2002;146.
3. del Pozo M.A., Sanchez-Mateos P., Nieto M., Sanchez-Madrid F. J. Cell Biol. 131:1995;495.
4. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Blood. 97:2001;2121.
5. Cather J.C., Menter A. Expert. Opin. Biol. Ther. 3:2003;361.
6. Mysliwiec J., Kretowski A., Kinalski M., Kinalska I. Immunol. Lett. 70:1999;69.
7. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., Hommel U. J. Mol. Biol. 292:1999;1.
8. Kelly T.A., Jeanfarve D.D., McNeil D.W., Woska J.R. Jr., Reilly P.L., Mainolfi E.A., Kishimoto K.M., Nabozny G.H., Zinter R., Bormann B.-J., Rothlein R. J. Immunol. 163:1999;5173.
9. Davidson W., Hopkins J.L., Jeanfarve D.D., Barney K.L., Kelly T.A., Grygon C.A. J. Am. Soc. Mass Spectrom. 14:2003;8.
10. Yusuf-Makagiansar H., Makagiansar I.T., Siahaan T.J. Inflammation. 25:2001;203.
11. Yusuf-Makagiansar H., Makagiansar I.T., Hu Y., Siahaan T.J. Peptides. 22:2001;1955.
12. Lynam E., Sklar L.A., Taylor A.D., Neelamegham S., Edwards B.S., Smith C.W., Simon S.I. J. Leukoc. Biol. 64:1998;622.
13. Anderson M.E., Siahaan T.J. Pharm. Res. 20:2003;1523.
14. Jois D.S., Pal D., Tibbetts S.A., Chan M.A., Benedict S.H., Siahaan T.J. J. Pept. Res. 49:1997;517.
15. Gursoy R.N., Jois D.S., Siahaan T.J. J. Pept. Res. 53:1999;422.
16. Casasnovas J.M., Stehle T., Liu J.H., Wang J.H., Springer T.A. Proc. Natl. Acad. Sci. U.S.A. 95:1998;4134.
17. Anderson M.E., Siahaan T.J. Peptides. 24:2003;487.
18. Morris G.M., Goodsell D.S., Huey R., Olson A.J. J. Comput.-Aided Mol. Des. 10:1996;293.
19. 2+-dependent binding studies suggest that the binding region of cIBR peptide is at the metal ion-dependent adhesion site (MIDAS) of the I-domain. The dimensions of the grid were 50.0×50.0×50.0 Å with grid points separated by 0.5 Å. All dihedral angles that can be rotated in the peptide side chains were assigned with the auxiliary program AutoTors and were allowed to rotate freely. A total of 128 runs were performed for each peptide and each simulation run lasted 110 cycles with a starting temperature of 616 K in the first cycle and a temperature reduction factor of 0.95 per cycle. The lowest energy structures produced by AutoDock runs were taken as the possible binding models.
20. Coulson B.S., Londrigan S.L., Lee D.J. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5389.
21. Lu X., Sun Y., Shang D., Wattam B., Egglezou S., Hughes T., Hyde E., Scully M., Kakkar V. Biochem. J. 355:2001;633.